WHO Sounds Alert Over Acute Lack of Obesity Jabs
Under a tenth of people that would benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it publishes its first recommendations on the therapies.
With over a billion individuals worldwide currently obese, it is urging broader and more equitable access to these injectable treatments.
Per estimates, over two billion are projected to be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a chronic disease that can be managed with comprehensive and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant obstacles to widespread availability to the injections that can help people shift significant weight, notes the organization.
Skinny Jab Supply Crisis
Despite the current most favorable scenario, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of those who need them, per the health organization.
The recommendation urges nations and manufacturers to widen availability, through measures like licensing agreements.
A patent on the active ingredient – the main ingredient of a leading brand – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Jabs Work
GLP-1 drugs replicate a natural hormone to reduce digestion speed, reduce hunger and boost the sense of being full so people consume fewer calories.
Individuals commonly start to lose weight within a few weeks of beginning the weekly injections.
Evidence indicates people may regain a significant portion after a year of discontinuing the drug, as their normal appetite resume.
Being above a healthy weight increases your chance for developing health problems, including type 2 diabetes, heart disease, stroke, and specific cancers.
Obesity concerns people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
